Vanda Pharmaceuticals FDA Approval, Nike CEO Stock Purchase, and 2025 SPX Performance

Vanda Pharmaceuticals FDA Approval

• 🚀 Vanda Pharmaceuticals is up 22% in pre-market trading following FDA approval for its drug, Nereus (tradipitant).
• 💡 This drug is the first approved in over 40 years for the prevention of motion-induced sickness, working by blocking a brain receptor linked to nausea.
• 🧠 The mechanism is similar to technology used in GLP-1 weight loss drugs, now applied to motion sickness.

Nike CEO's Confidence Boost

• 📈 Nike shares rose 2.2% after CEO Elliot Hill purchased approximately $1 million worth of shares.
• 🎯 This purchase signals confidence in the CEO's turnaround strategy, especially after Tim Cook's recent $3 million investment.
• 📉 Despite the positive move, Nike shares are still down around 19% year-to-date, with many retailers struggling due to tariffs and economic uncertainty.

2025 SPX Performance and Sector Trends

• 📊 The S&P 500 Index is projected to end 2025 up over 17%, continuing a bull market driven by artificial intelligence enthusiasm.
• 💾 The AI trade broadened beyond chip stocks to include companies involved in building data centers, with SanDisk, Western Digital, Micron, and Seagate being top performers.
• 📉 Retailers like Deckers Outdoor and Lululemon struggled, down significantly year-to-date due to tariff costs, consumer behavior pullback, and increased competition.